Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03819803 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Fecal Microbiota Transplantation in aGvHD After ASCT

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 2, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv7
  2. Primary completion date: Mar 1, 2024 to Mar 1, 2026 Completion date: Dec 31, 2024 to Dec 31, 2026v6 Show 1 more changeShow less
    • Completion date: Dec 31, 2024 to Dec 31, 2026
  3. Primary completion date: Mar 1, 2022 to Mar 1, 2024 Completion date: Dec 31, 2022 to Dec 31, 2024v5 Show 1 more changeShow less
    • Completion date: Dec 31, 2022 to Dec 31, 2024
  4. Re-verified, no change to tracked fieldsv4
  5. Primary completion date: Mar 1, 2020 to Mar 1, 2022 Completion date: Dec 31, 2020 to Dec 31, 2022v3 Show 1 more changeShow less
    • Completion date: Dec 31, 2020 to Dec 31, 2022
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Acute graft-versus-host-disease (aGvHD) is a typical complication after allogeneic hematopoetic stem cell transplantation (ASCT). About 30-60% of patients after ASCT are affected by aGvHD, which constitutes a relevant burden of morbidity and mortality in these patients. Fecal microbiota transplantation (FMT) is a therapeutic concept to treat intestinal dysbiosis of various origin by infusion of the stool microbiota of a healthy donor into the gastrointestinal tract (GI) of a patient. FMT can be performed endoscopically by colonoscopic deployment of the donor microbiota into the patient´s caecum and terminal ileum. Patients with gastrointestinal aGvHD (GI-aGvHD) are known to comprise a significant dysbiotic colonic microbiota that can be attenuated by FMT.
Trial Details
NCT Number NCT03819803
Lead Sponsor Medical University of Graz
Conditions Graft Versus Host Disease in GI Tract
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov